We are live on
!
Find out more
BCM
BML Capital Management Portfolio holdings
AUM
$156M
1-Year Est. Return
129.82%
This Fund
S&P 500
This Quarter
Est. Return
+28.58%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$156M
AUM Growth
+$40.1M
(+35%)
Cap. Flow
+$10.8M
Cap. Flow
% of AUM
6.95%
Top 10 Holdings %
Top 10 Hldgs %
94.02%
Holding
19
New
3
Increased
3
Reduced
1
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Outset Medical
OM
|
+$5.57M |
| 2 |
Tilly's
TLYS
|
+$4.34M |
| 3 |
Kraft Heinz
KHC
|
+$2.94M |
| 4 |
Janux Therapeutics
JANX
|
+$2.12M |
| 5 |
IMA
ImageneBio Inc
IMA
|
+$154K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$1.98M |
| 2 |
Lisata Therapeutics
LSTA
|
+$136K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.34% |
| 2 | Consumer Discretionary | 9.73% |
| 3 | Consumer Staples | 4.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Aclaris Therapeutics
ACRS
$793M
| $53.4M | 34.31% |
14,250,000
| – | – |
|
|
2
Atea Pharmaceuticals
AVIR
$390M
| $38M | 24.38% |
7,058,657
-431,343
| -6% | -$1.98M |
|
3
Oramed Pharmaceuticals
ORMP
$165M
| $10.8M | 6.91% |
3,167,231
| – | – |
|
|
4
Tilly's
TLYS
$121M
| $8.71M | 5.59% |
+2,150,000
| New | +$4.34M |
|
|
5
Outset Medical
OM
$77.9M
| $7.3M | 4.69% |
1,902,201
+1,359,021
| +250% | +$5.57M |
|
6
PMV Pharmaceuticals
PMVP
$71.5M
| $6.6M | 4.24% |
5,320,000
+28,000
| +0.5% | +$35.6K |
|
7
CarMax
KMX
$8.14B
| $6.44M | 4.14% |
155,000
| – | – |
|
|
KZR
8
DELISTED
Kezar Life Sciences
KZR
| $5.35M | 3.43% |
720,787
| – | – |
|
9
Instil Bio
TIL
$50.3M
| $5.32M | 3.42% |
645,600
| – | – |
|
10
Target
TGT
$63.4B
| $4.54M | 2.92% |
37,500
| – | – |
|
|
11
Kraft Heinz
KHC
$30.7B
| $2.81M | 1.8% |
+125,000
| New | +$2.94M |
|
|
12
Janux Therapeutics
JANX
$992M
| $2.15M | 1.38% |
+154,961
| New | +$2.12M |
|
13
Pliant Therapeutics
PLRX
$71.2M
| $1.95M | 1.25% |
1,546,137
| – | – |
|
|
CNTB
14
Connect Biopharma Holdings
CNTB
$150M
| $1.07M | 0.69% |
408,887
| – | – |
|
|
IMA
15
ImageneBio Inc
IMA
$60.7M
| $1M | 0.64% |
200,730
+23,704
| +13% | +$154K |
|
16
PUT
Walmart Inc
WMT
$909B
| $329K | 0.21% |
335
| – | – |
|
17
PUT
Carvana
CVNA
$48.2B
| – | – |
-750
| Closed | -$2.02M |
|
|
18
Lisata Therapeutics
LSTA
$32.8M
| – | – |
-73,348
| Closed | -$136K |
|
19
PUT
Tesla
TSLA
$1.43T
| – | – |
-1,000
| Closed | -$205K |
|
Similar funds
AIS
BWM
TI
CFG
IWA
PFO
HCWM
BCM
BML Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, BML Capital Management held 19 positions worth $156M, up 35% from $116M the previous quarter. Its ten largest holdings account for 94% of the portfolio.
BML Capital Management deployed $10.8M of net new capital in Q1 2026, opening 3 new positions and adding to 3 existing holdings. Its largest new stake was Tilly's: 2,150,000 shares worth $8.71M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $1.98M trimmed.
- BML Capital Management's largest Q1 2026 buy was Tilly's: 2,150,000 shares worth $8.71M.
- BML Capital Management added most to Outset Medical in Q1 2026, an estimated $5.57M increase.
- BML Capital Management's biggest Q1 2026 reduction was Atea Pharmaceuticals, cutting an estimated $1.98M.
- BML Capital Management fully exited Lisata Therapeutics in Q1 2026, selling an estimated $136K.
- BML Capital Management's ten largest holdings make up 94% of its $156M portfolio in Q1 2026.
- BML Capital Management opened 3 new positions and closed 3 in Q1 2026.
- BML Capital Management's portfolio value rose 35% quarter-over-quarter to $156M.
Based on BML Capital Management's 13F filing for Q1 2026, filed 6 May 2026.